INMB

INmune Bio Inc

INMB, USA

INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, which is in Phase II for the treatment of breast cancer. It provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression; and CORDstrom, a cell suspension for intravenous infusion or injection comprising aseptic, allogeneic, and pooled HucMSCs. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.

https://www.inmunebio.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
INMB
stock
INMB

INmune Bio (NASDAQ:INMB) Rating Increased to Hold at Wall Street Zen Defense World

Read more →
INMB
stock
INMB

INmune Bio (NASDAQ:INMB) Rating Increased to Hold at Wall Street Zen Defense World

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$5.25

Analyst Picks

Strong Buy

2

Buy

3

Hold

0

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Medium

2.11

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-25.50 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-19.40 %

Low ≤ 2%

High ≥ 10%

Debt to Equity

-

Very High

0.31

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 24.72% of the total shares of INmune Bio Inc

1.

BlackRock Inc

(4.4101%)

since

2025/06/30

2.

Vanguard Group Inc

(3.1888%)

since

2025/06/30

3.

Vanguard Total Stock Mkt Idx Inv

(1.8019%)

since

2025/07/31

4.

UBS Group AG

(1.6897%)

since

2025/06/30

5.

iShares Russell 2000 ETF

(1.5295%)

since

2025/08/31

6.

Geode Capital Management, LLC

(1.4667%)

since

2025/06/30

7.

State Street Corp

(1.0359%)

since

2025/06/30

8.

Dauntless Investment Group, LLC

(0.9349%)

since

2025/06/30

9.

Rhenman Partners Asset Management AB

(0.6706%)

since

2025/06/30

10.

Rhenman Healthcare Equity L/S RC2 SEK

(0.6706%)

since

2025/05/31

11.

Fidelity Small Cap Index

(0.6349%)

since

2025/06/30

12.

Northern Trust Corp

(0.6185%)

since

2025/06/30

13.

Vanguard Institutional Extnd Mkt Idx Tr

(0.5667%)

since

2025/07/31

14.

iShares Russell 2000 Growth ETF

(0.5486%)

since

2025/08/31

15.

XTX Topco Ltd

(0.4734%)

since

2025/06/30

16.

Morgan Stanley - Brokerage Accounts

(0.3864%)

since

2025/06/30

17.

Fidelity Extended Market Index

(0.3172%)

since

2025/07/31

18.

Vanguard Russell 2000 ETF

(0.2967%)

since

2025/07/31

19.

JPMorgan Chase & Co

(0.275%)

since

2025/06/30

20.

SIMPLEX TRADING, LLC

(0.2646%)

since

2025/06/30

21.

Bank of New York Mellon Corp

(0.2317%)

since

2025/06/30

22.

Charles Schwab Investment Management Inc

(0.1949%)

since

2025/06/30

23.

Buckingham Strategic Partners

(0.1836%)

since

2025/06/30

24.

Royal Bank of Canada

(0.1835%)

since

2025/06/30

25.

Mccormack Advisors International

(0.1814%)

since

2025/06/30

26.

Scientech Research LLC

(0.172%)

since

2025/06/30

27.

LPL Financial Corp

(0.1624%)

since

2025/06/30

28.

Millennium Management LLC

(0.1603%)

since

2025/06/30

29.

State St Russell Sm Cap® Indx SL Cl I

(0.1576%)

since

2025/08/31

30.

Schwab Small Cap Index

(0.1573%)

since

2025/07/31

31.

NT R2000 Index Fund - NL

(0.1518%)

since

2025/06/30

32.

Extended Equity Market Fund K

(0.1425%)

since

2025/06/30

33.

iShares Micro-Cap ETF

(0.1399%)

since

2025/08/31

34.

SPDR® Russell 2000 US Small Cap ETF

(0.1254%)

since

2025/08/31

35.

NT R2000 Index Fund - DC - NL - 3

(0.1211%)

since

2025/06/30

36.

Russell 2500™ Index Fund F

(0.1169%)

since

2025/06/30

37.

Fidelity Total Market Index

(0.1105%)

since

2025/07/31

38.

iShares Russell 2000 Small-Cap Idx Instl

(0.0916%)

since

2025/07/31

39.

Fidelity Series Total Market Index

(0.0813%)

since

2025/07/31

40.

Russell 2000 Index Non-Lendable Fund E

(0.077%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

-0.24

EPS Estimate

-0.325

EPS Difference

0.085

Surprise Percent

26.1538%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(4.5)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(3.8)
GARP
Not Attractive for GARP(2)
Growth
Weak Growth Prospect(0.5)
Momentum
No Momentum(2.5)
Net Net
Possible Net-Net(3.5)
Quality
Low Quality Business(2.5)
Value
Fair Value(4.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.